Visomitin-SKQ1-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVisomitinCat. No.: HY-100474CAS No.: 934826-68-3Synonyms: SKQ1分式: CHBrOP分量: 617.6作靶點: Reactive Oxygen Species作通路: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-B儲存式: Pure form -20C 3 years4C 2 yearsIn solvent -80C 6 mon

2、ths-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 29 mg/mL (46.96 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.6192 mL 8.0959 mL 16.1917 mL5 mM 0.3238 mL 1.6192 mL 3.2383 mL10 mM 0.1619 mL 0.8096 mL 1.6192 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和

3、給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.05 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.05 mM); Cl

4、ear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Visomitin種新型抗氧化劑，具有最的線粒體穿透能和有效的抗氧化能。體外研究 Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicityagainst Panc02 cells. While Visomitin does not affect viability of

5、 the cell lines, this drug at 500 nMconcentration reduces heavily the proliferation of human PDAC cells 1.體內(nèi)研究 Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC)bearing mice a decrease in KC in the group of continuous treatment with Visomitin (S

6、kQ1). Treatment of themice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced inall Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 andIL-13 amount is found in the Visomitin treated groups. TGF-b

7、 amount is decreased in the pretreatmentsetting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. TheVisomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does notreach the level of significance defined 1.PROTOCOLCell

8、Assay 1 Panc02 cells are treated 48 h with different concentrations of Visomitin (SkQ1). Cell viability after Visomitintreatment is measured with an EZ4U Kit as described by the manufacturers. Briey, 20,000 cells per well areseeded in 96-wellplates and let grow overnight. Afterwards, cells are treat

9、ed without the medium exchange.A substrate compound from the kit is added and the cells are further incubated for 5 hr at 37C to convert theyellow colored tetrazolium to its red formazan derivate by living cells. The absorbance is measured at 450 nm1.MCE has not independently confirmed the accuracy

10、of these methods. They are for reference only.Animal Female C57BL/6 mice are used in this study. For experiments on both acute and chronic pancreatitis, miceAdministration 2 are divided in three groups. Group A (acute pancreatitis (AP) n=8; chronic pancreatitis (CP) n=12) is treatedwith 5nmol/kg Vis

11、omitin (SkQ1), group B (AP n=8; CP n=12) is the untreated control, and group C (AP n=8;CP n=7) is the sham group, which is injected intraperitoneally with 0.9% NaCl instead of cerulein and istherefore the negative control group without pancreatitis. For experiments on acute pancreatitis, mice arepre

12、treated with Visomitin for 8 weeks prior to induction of pancreatitis. Mice designated for experiments onchronic pancreatitis receive Visomitin at the same concentration for 8 weeks in parallel with induction ofpancreatitis 2.MCE has not independently confirmed the accuracy of these methods. They ar

13、e for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Redox Biol. 2018 Oct;19:339-353.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEREFERENCES1. Bazhin AV, et al. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murineorthotopic model of pancreatic cancer. Int J Cancer. 2016 Jul 1;139(1):130-9.2. Weniger M, et al. The Analgesic Effect of the Mitochondria-Targeted Antioxidant SkQ1 in Pancreatic Inflammation. Oxid Med CellLongev. 2016;2016:465